Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2007-11-06
2007-11-06
Schwadron, Ronald B. (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S139100, C424S152100, C424S158100, C424S172100, C514S002600, C514S834000, C530S388250, C530S389300, C435S337000
Reexamination Certificate
active
08323060
ABSTRACT:
A method of inhibiting microvascular bleeding is provided. Antibody to protein C administered to a patient in a pharmaceutically acceptable carrier prevents anticoagulation by greater than 90% of activated protein C in human plasma.
REFERENCES:
patent: 5084273 (1992-01-01), Hirahara
patent: 5093117 (1992-03-01), Lawrence et al.
patent: 5130244 (1992-07-01), Nishimaki et al.
patent: 5147638 (1992-09-01), Esmon et al.
patent: 5202253 (1993-04-01), Esmon et al.
patent: WO 94/22470 (1994-10-01), None
Suzuki et al. Thrombosis Research 53; 271-277, 1989.
Waldmann, Science, vol. 252, 1657-62, 1991.
Harris et al., TIBTECH, vol. 11, p. 42-44, 1993.
Broze, Sem. Hematol. , vol. 29, 159-169, 1992.
Taylor et al., Trauma, 30, 5197-203, 1990.
Taylor et al., J. Clin. Inv., 79, 918-925, 1987.
Taylor et al., Blood, 78, 357-363, 1991.
Rhein, Biotechnology Newswatch, Oct. 4, 1993, pp. 1 and 3.
Fusker et al., “Spontaneous Arterial Lesions in Normal Pigs With Von Willebrand's Disease” pp. 315-317, From: Artherosclerosis Metabolic, Morphologic and Clinical Aspects, Ed. G. W. Manning, Plenum Press, 1977.
Fusker et al., “Interactions of Platelets With the Endothelium in Normal and Von Willebrand Pigs”, pp. 187-196, From Thrombosis Animal and Clinical Models, Ed. H. J. Day et al., Plenum Press, 1977.
Bowie et al., J. Clin. Inv., 78: 26-30, 1986.
Cheesebro et al., Circulation, 86, No. 6, Supplement III, 100-110, 1992.
Fass et al., Thrombosis Res., 8: 319-327, 1976.
Montagwa et al., J. Inv. Derm., 43:11-22, 1964.
Griggs et al., Am. J. Path., 102:137-145, 1981.
Furie et al. , Cell, 53: 505-518, 1988.
Bauer, K.A. and R. D. Rosenbrg, “Congenital antithrombin III deficiency: Insights into the pathogenesis of the hypercoagulable state and its management using markers of hemostatic system activation,”Am.J.Med.87:39S-43S (1989).
Bauer, K.A. and R.D. Rosenberg, “Role of antithrombin III as a regulator of in vivo coagulation,”Semin.Hematol.28:10-18 (1991).
Broze, G.J., Jr., et al., “The lipoprotein-associated coagulation inhibitor,”Prog.Hemost.Thromb. 10:243-268 (1991).
Broze, G.J., Jr., et al., “Regulation of coagulation by a multivalent Kunitz-type inhibitor,”Biochemistry. 29:7539-7546 (1990).
Chesebro, James H., et al., “Antithrombotic Therapy and Proression of Coronary Artery Disease,”Circulation Supplement III, 86(6):III-100-!!!-110 (1992).
Clouse, L.H. and Comp, P.C., “The regulation of hemostatis: The protein C system,”N, Engl. J. Med. 314(20):1298 (1986).
Comp, P.C. and Esmon, C.T., “Generation of fibrinolytic activity by infusion of activated protein C into dogs,”J. Clin. Invest. 68:1221 (1981).
Comp, P.C., et al. , “Familial protein S deficiency is associated with recurrent thrombosis,”J. Clin, Invest. 74:2082-2088 (1984).
Comp, P.C., et al., “Activation of protein C in vivo,”J.Clin.Invest. 70: 127-134 (1987).
Comp. P.C., “Hereditary disorders predisposing to throbosis,” In B.S. Coller (Ed.),Progress in Hemostasis and Thrombosis. (New York: Grune and Stratton, 1986). vol. 8, pp. 71-102.
Conway, E.M. and R.D. Rosenberg, “Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells,”Mol.Cell.Biol. 8:5588-5592 (1988).
Cooper, D.K.C., et al., “The Pig as Potential Organ Donor for Man,” Chapter 30, 481-500.
Dahlback, B., “Interaction between vitamin K-dependent protein S and the complement protein, C4b-binding protein. A link between coagulation and the complement system,”Semin.Thromb.Hemost. 10:139-148 (1984).
Dahlback, B., “Inhibition of protein Ca cofactor function of human and bovine protein S by C4b-binding protein,”J.Biol.Chem.261:12022-12027 (1986).
Dahlback, B., “Interaction between complement component C4b-binding protein and the vitamin K-dependent protein S. A link between blood coagulation and the complement system,”Scand.J.Clin.Lab.Invest. [Suppl] 177:33-41 (1985).
de Fouw, N.J., et al., “The cofactor role of protein S in the acceleration of whole blood clot lysis by activated protein C in vitro,” Blood 67:1189-1192 (1986).
Esmon, C.T,, et al., “Interaction of thrombin with thrombomodulin,”Ann. N.Y. Acad. Sci.485: 215 (1986).
Esmon, C.T., “The roles of protein C and thrombomodulin in the regulation of blood coagulation,”J. Biol. Chem. 264(9): 4743 (1989).
Esmon, N.L., “Thrombomodulin,” Semin.Thromb.Hemost. 13:454-463 (1987).
Flaherty, M.J., et al. “Iatrogenic immunization with bovine thrombin: A mechanism for prolonged thrombin times after surgery,”Ann. Int. Med. 111: 631 (1989).
Flaherty, M.J. and Wener, M.H., “Antibodies to thrombin in postsurgical patients,”Blood73(5):1386 (1989).
Fulcher, C.A. et al., “Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with V,”Blood63:486-49 (1984).
Hillarp, A. and B. Dahlback, “The protein S-binding site localized to the central core of C4b-binding protein,”J. Biol. Chem. 262:11300-11307 (1987).
Kirkman, Robert L., “Of swine and men: organ physiology in different species,”Xenograft25 Mark A. Hardy (Ed.), 1989 Elsevier Science Publishers (Biomedical Division).
Kisiel, W., et al., “Anti-coagulant properties of bovine plasma protein C following activation by thrombin,”Biochemistry16: 5824 (1977).
Kisiel, W., “Human plasma protein C: Isolation, characterization and mechanism of activation by alpha-thrombin,”J. Clin. Invest. 64:761 (1979).
Lentz, S.R., et al., “Regulation of thrombomodulin by tumor necrosis factor-alpha: comparison of transcriptional and post-transcriptional mechanism,”Blood77:542-550 (1991).
Marlar, R.A., et al., “Human protein C: inactivation of factors V and VIII in the activated molecule,”Ann.NY.Acad.Sci. 370:303-10 (1981).
Melissari and Kakkar, “Congenital severe protein C deficiency in adults,”Br. J. Haematol. 72(2):222-228 (1989).
Menache, D., “Antithrombin III: introduction,”Semin.Hematol. 28:1-2 (1991).
Miletich, J.P., “Laboratory diagnosis of protein C deficiency,”Semin. Thromb. Hemost.16(2):169 (1990).
Miletich, J., et al., “Absence of thrombosis in subjects with heterozygous protein C deficiency,”N. Engl. J. Med. 317(16):991 (1987).
Moore, K., et al., “Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro,”J.Clin.Invest. 79:124-130 (1987).
Moore, K.L., et al., “Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture Indianapolis,”Blood73:159-165 (1989).
Muller, James E., “Coronary Artery Thrombosis: Historical Aspects,”J. Am. Coll. Cardiol. 1(3):893-896 (1983).
Nawroth, P.P., et al., “Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity,”Proc.Natl.Acad.Sci.USA83:3460-344 (1986).
Nawroth, P.P. and D.M. Stern, “Modulation of endothelial cell hemostatic properties by tumor necrosis factor,”J.Exp.med.163:740-745 (1986).
Owen, W.G. and Esmon, C.T., “Functional properties of an endothelial cell cofactor for thrombin-catalyzed activation of protein C,”J. Biol. Chem. 256:5532 (1981).
Prelssner, K.T., “Biological relevance of the protein C system and laboratories diagnosis of protein C and protein S deficiencies,”Clin. Sci.78: 351, 1990.
Rapaport, S.I., “Inhibition of factor VIIa/tissue factor-induced blood coagulation: with particular emphasis upon a factor Xa-dependent inhibitory mechanism 92013,”Blood73:359-365 (1989).
Rapaport. S.I., “The extrinsic pathway inhibitor: a regulator of tissue factor-dependent blood coagulation,”Thromb.Haemost. 66 (1):6-15 (
Fulbright & Jaworski LLP
Oklahoma Medical Research Foundation
Schwadron Ronald B.
LandOfFree
Blockade of protein C activation reduces microvascular... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Blockade of protein C activation reduces microvascular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blockade of protein C activation reduces microvascular... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3808894